Skip to main content
. 2024 Oct 7;43(12):2397–2406. doi: 10.1007/s10096-024-04956-y

Table 4.

Specificity (untreated healthy individuals) and negativity rates (treated healthy individuals and cross-reactivity controls) of the test strategies

uHI tHI CR
n = 75 n = 15 n = 16
npos %neg [95% CI] npos %neg [95% CI] npos %neg [95% CI]
STTT
  Ser-RL 5 93 [85 − 98] 2 87 [60 − 98] 0 100 [80 − 100]
  Lia-RL 5 93 [85 − 98] 2 87 [60 − 98] 0 100 [80 − 100]
  C6-RL 4 95 [87 − 99] 0 100 [78 − 100] 0 100 [80 − 100]
  Ser-EU 8 89 [80 − 95] 2 87 [60 − 98] 5 69 [41 − 89]
  Lia-EU 8 89 [80 − 95] 2 87 [60 − 98] 4 75 [48 − 93]
  C6-EU 4 95 [87 − 99] 0 100 [78 − 100] 1 94 [70 − 100]
MTTT
  Ser-Lia 9 88 [78 − 94] 2 87 [60 − 98] 4 75 [48 − 93]
  Ser-C6 5 93 [85 − 98] 0 100 [78 − 100] 1 94 [70 − 100]
  Lia-C6 5 93 [85 − 98] 0 100 [78 − 100] 2 88 [62 − 98]

uHI: untreated healthy individuals, tHI: treated healthy individuals, CR: cross-reactivity controls, Ser: Serion, Lia: Liaison, C6: C6 Lyme ELISA, RL: recomLine, EU: Euroline, STTT: standard two-tier testing, MTTT: modified two-tier testing